Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: A cross-sectional study

Diabetes and Vascular Disease Research

Volumn 5, Issue 1, 2008, Pages 19-24

  Ybarra, Juan ^b   Planas, Francesc ^b   Pou, Jose M ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO MÉDICO TEKNON   (Spain)

Author keywords

Berlin Questionnaire; Diastolic dysfunction; HOMA index; Morbid obesity; NT proBNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; FEMALE; HEART LEFT VENTRICLE FAILURE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OBESITY; QUESTIONNAIRE; SLEEP DISORDERED BREATHING;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBESITY, MORBID; PEPTIDE FRAGMENTS; QUESTIONNAIRES; SLEEP APNEA SYNDROMES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 41949098606     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2008.004     Document Type: Article

References (47)

1. Allison DB, Fontaine KR, Manson JE, Stevens J, Vanltallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530-8.
2. World Health Organization. Obesity: preventing and managing the global epidemic. World Health Organization: Geneva, Switzerland, 1998.
3. Fritscher LG, Dixon JB, Mottin C, Cananis S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg 2007;17:95-9.
4. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med 1996; 334:99-104.
5. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.
6. Tasali E, Van Cauter E. Sleep-disordered breathing and the current epidemic of obesity: consequence or contributing factor? Am J Respir Crit Care Med 2002;165:562-3.
7. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lindl L. Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334-41.
8. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-43.
9. Avelar E, Cloward TV, Walker JM et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 2007;49:34-9.
10. Evrengul H, Dursunoglu D, Kaftan A, Klicaslan F, Tanriverdi H, Klic M. Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension. Acta Cardiol 2005;60:191-8.
11. Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998;53(suppl 3):S25-S28.
12. Melanson SE, Lewandrowski EL. Laboratory testing for B-type natriuretic peptides (BNP and NT-proBNP): clinical usefulness, utilization, and impact on hospital operations. Am J Clin Pathol 2005;124(suppl):S122-S128.
13. Costello-Boerrigter LC, Boerrigter G et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53.
14. Anwaruddin S, Lloyd-Jones DM, Baggish A et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-7.
15. Morricone L, Malavazos AE, Coman C, Donati C, Hassan T, Caviezel F. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 2002;10:489-97.
16. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
17. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
18. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007;167:400-07.
19. Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-8.
20. Van Kimmenade R, van Dielen F, Bakker J et al. Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol 2006;47:886-7.
21. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-91.
22. Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:36-42.
23. Alam M, Wardell J, Anderson E, Samad BA, Nordlander R. Characteristics of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue imaging in healthy subjects. J Am Soc Echocardiogr 1999;12:618-28.
24. Devereux RB, Reiche N. Echocardiographic determination of left ventricular mass in man. Anatomic evaluation of the method. Circulation 1977;55:613-18.
25. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987;59:956-60.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-19.
27. Karl J, Borgya A, Gallusser A et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81.
28. Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.
29. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.
30. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1175-80.
31. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 2002;3:401-04.
32. Svatikova A, Wolk R, Gami AS, Pohanka M, Somers VK. Interactions between obstructive sleep apnea and the metabolic syndrome. Curr Diab Rep 2005;5:53-8.
33. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Sleep apnea and day-time sleepiness and fatigue relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
34. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002;165:677-82.
35. Vgontzas AN, Legro R, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517-20.
36. Ip S, Lam B, Ng M, Lam W, Tsang K, Lam K. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670-6.
37. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9.
38. Olsen MH, Hansen TW, Christensen MK et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660-6.
39. McCord J, Mundy BJ, Hudson MP et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247-52.
40. Wang TJ, Larson MC, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600.
41. St Peter JV, Hartley GG, Murakami MM, Apple FS. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006;52:680-5.
42. Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 1998;11:296-9.
43. Minami J, Nishikimi T, Matsuoka H. Plasma brain natriuretic peptide and N-terminal proatrial natriuretic peptide level in obese patients: a cause or result of hypertension [letter]? Circulation 2004;110:e76.
44. Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. Sleep apnea and sleep disruption in obese patients. Arch Intern Med 1994;154:1705-11.
45. Bearpark H, Elliott L, Grunstein R et al. Snoring and sleep apnea: a population study in Australian men. Am J Respir Crit Care Med 1995;151:1459-65.
46. Malavazos AE, Morricone L, Marocchi A, Ermetici F, Ambrosi B, Corsi MM. N-terminal pro-B-type natriuretic peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin Chem 2006;52:1211-13.
47. Hermann-Arnhof KM, Hanusch-Enserer U, Kaestenbauer T et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem 2005;51:138-43.